RBRachana Bhattarai

Rachana Bhattarai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rachana Bhattarai has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Christine M. Budke

    Department of Veterinary Integrative Biosciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX, USA

    5 shared publications
  • Hélène Carabin

    University of Oklahoma Health Sciences Center, Department of Biostatistics and Epidemiology, Oklahoma City, Oklahoma, United States

    5 shared publications
  • Ana Flisser

    MSc National Autonomous University of Mexico

    4 shared publications
  • Jefferson V. Proaño

    Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, México DF, Mexico

    4 shared publications
  • Teresa Corona

    Clinical Laboratory of Neurodegenerative Diseases, National Institute of Neurology and Neurosurgery, México DF, Mexico

    3 shared publications
  • Jose Flores-Rivera

    Clinical Laboratory of Neurodegenerative Diseases, National Institute of Neurology and Neurosurgery, México Distrito Federal, Mexico

    2 shared publications

Latest Publications

  • Local public health response to first Candida auris outbreak spanning 28 healthcare facilities—Maricopa County, Arizona, April 2022–February 2023

    by Heather L. Leahy, Serena Bailey, JulieAnna Rivas, Monica Hernandez-Cubias, Kaitlyn Chorbi, Bianca Munoz, Rachana Bhattarai, Zoha Ahmed, Ariella P. Dale, Karen Zabel, et al.

    Objective: Describe the first healthcare-associated outbreak of Candida auris in Maricopa County, Arizona. Also, outline the Maricopa County Department of Public Health (MCDPH) response activities to halt transmission and identify affected healthcare facilities (HCFs) and contacts colonized with C. auris . Methods: At HCFs with confirmed C. auris cases (i.e., exposed HCFs), MCDPH provided virtual infection control assessment and response activities, including contact investigations among hospitalized patients and point prevalence surveys (PPSs) to identify ongoing transmission. Confirmed C. auris cases included C. auris detected by cultures or polymerase chain reaction (PCR) in a hospitalized patient. Clinical cases had C. auris from cultures obtained during routine care in a hospitalized patient. Colonized cases included C. auris detected by PCR obtained from hospitalized patients for screening purposes. Results: On April 21, 2022, the first clinical case was identified, resulting in an outbreak with C. auris screening at 28 exposed HCFs. In total, 39 clinical C. auris cases were reported. Among 1,994 contacts identified, 899 (45.0%) were screened, 8 (0.4%) declined screening, and 1,087 (54.5%) were ineligible for screening (i.e., no longer hospitalized in Maricopa County). Among screened patients, 158 (17.6%) were colonized with C. auris ; 15 (9.5%) colonized contacts later acquired clinical infections. This outbreak concluded on February 23, 2023, after 2 consecutive PPSs yielded no C. auris detection at exposed HCFs. Conclusions: The first C. auris outbreak in Maricopa County highlights the coordinated efforts between HCFs, laboratories, and public health to identify exposed HCFs, screen contacts, and halt C. auris transmission.

  • Open Access

    Pre-hospitalization, hospitalization, and post-hospitalization costs of patients with neurocysticercosis treated at the Instituto Nacional de Neurologia y Neurocirugia (INNN) in Mexico City, Mexico

    by Rachana Bhattarai, Hélène Carabin, Jose Flores-Rivera, Teresa Corona, Jefferson V. Proaño, Ana Flisser, Christine M. Budke

    The objective of this study was to estimate the direct costs associated with the diagnosis and treatment of neurocysticercosis (NCC) during pre-hospitalization, hospitalization, and post-hospitalization periods for 108 NCC patients treated at the Instituto Nacional de Neurologia y Neurocirugia (INNN) in Mexico City, Mexico. Information on clinical manifestations, diagnostic tests, hospitalizations, surgical procedures, prescription medication, and other treatments was collected via medical chart reviews. Uncertain values for costs and frequency of treatments were imputed using bootstrap techniques. The average per-patient pre-hospitalization and hospitalization costs were US$ 257 (95% CI: 185 – 329) and US$ 2,576 (95% CI: 2,244 – 2,908), respectively. Post-hospitalization costs tended to decrease over time, with estimates for the first five years post-hospitalization of US$ 475 (95% CI: 423 – 527), US$ 228 (95% CI: 167 – 288), US$ 157 (95% CI: 111 – 202), US$ 150 (95% CI: 106 – 204), and US$ 91 (95% CI: 27 – 154), respectively. NCC results in a significant economic burden for patients requiring hospitalization, with this burden continuing years post-hospitalization.


  • Cost of neurocysticercosis patients treated in two referral hospitals in Mexico City, Mexico

    by Rachana Bhattarai, Hélène Carabin, Jefferson V. Proaño, Jose Flores‐Rivera, Teresa Corona, Ana Flisser, Christine M. Budke

    Objectives: To estimate annual costs related to the diagnosis, treatment and productivity losses among patients with neurocysticercosis (NCC) receiving treatment at two referral hospitals, the Instituto Nacional de Neurologia y Neurocirugia (INNN) and the Hospital de Especialidades of the Instituto Mexicano del Seguro Social (HE‐IMSS), in Mexico City from July 2007 to August 2008.Methods: Information on presenting clinical manifestations, diagnostic tests, hospitalisations, surgical procedures and other treatments received by NCC outpatients was collected from medical charts, and supplemented by an individual questionnaire regarding productivity losses and out‐of‐pocket expenses related to NCC.Results: The annual average per‐patient direct costs were US$ 503 (95% CI: 414–592) and US$ 438 (95% CI: 322–571) for patients without a history of hospitalisation and/or surgery seen at the INNN and the HE‐IMSS, respectively. These costs increased to US$ 2506 (95% CI: 1797–3215) and US$ 2170 (95% CI: 1303–3037), respectively, for patients with a history of hospitalisation and/or surgery. The average annual per‐patient indirect costs were US$ 246 (95% CI: 165–324) and US$ 114 (95% CI: 51–178), respectively, using minimum salary wages for individuals not officially employed.Conclusions: The total annual cost for patients who had and had not been hospitalised and/or undergone a surgical procedure for the diagnosis or treatment of NCC corresponded to 212% and 41% of an annual minimum wage salary, respectively. The disease tends to affect rural socioeconomically disadvantaged populations and creates health disparities and significant economic losses in Mexico.


  • Open Access

    A Systematic Review of the Literature on Cystic Echinococcosis Frequency Worldwide and Its Associated Clinical Manifestations

    by Christine M. Budke, Hélène Carabin, Patrick C. Ndimubanzi, Hai Nguyen, Elizabeth Rainwater, Mary Dickey, Rachana Bhattarai, Oleksandr Zeziulin, Men-Bao Qian

    A systematic literature review of cystic echinoccocosis (CE) frequency and symptoms was conducted. Studies without denominators, original data, or using one serological test were excluded. Random-effect log-binomial models were run for CE frequency and proportion of reported symptoms where appropriate. A total of 45 and 25 articles on CE frequency and symptoms met all inclusion criteria. Prevalence of CE ranged from 1% to 7% in community-based studies and incidence rates ranged from 0 to 32 cases per 100,000 in hospital-based studies. The CE prevalence was higher in females (Prevalence Proportion Ratio: 1.35 [95% Bayesian Credible Interval: 1.16–1.53]) and increased with age. The most common manifestations of hepatic and pulmonary CE were abdominal pain (57.3% [95% confidence interval [CI]: 37.3–76.1%]) and cough (51.3% [95% CI: 35.7–66.7%]), respectively. The results are limited by the small number of unbiased studies. Nonetheless, the age/gender prevalence differences could be used to inform future models of CE burden.


  • Open Access

    The Burden of Cysticercosis

    by Rachana Bhattarai, Helene Carabin, Christine Budke

    The Burden of Cysticercosis | InTechOpen, Published on: 2013-01-30. Authors: Rachana Bhattarai, Hélène Carabin and Christine Budke


  • Open Access

    Estimating the Non-Monetary Burden of Neurocysticercosis in Mexico

    by Rachana Bhattarai, Christine M. Budke, Hélène Carabin, Jefferson V. Proaño, Jose Flores-Rivera, Teresa Corona, Renata Ivanek, Karen F. Snowden, Ana Flisser

    Neurocysticercosis (NCC) is a major public health problem in many developing countries where health education, sanitation, and meat inspection infrastructure are insufficient. The condition occurs when humans ingest eggs of the pork tapeworm Taenia solium, which then develop into larvae in the central nervous system. Although NCC is endemic in many areas of the world and is associated with considerable socio-economic losses, the burden of NCC remains largely unknown. This study provides the first estimate of disability adjusted life years (DALYs) associated with NCC in Mexico. DALYs lost for symptomatic cases of NCC in Mexico were estimated by incorporating morbidity and mortality due to NCC-associated epilepsy, and morbidity due to NCC-associated severe chronic headaches. Latin hypercube sampling methods were employed to sample the distributions of uncertain parameters and to estimate 95% credible regions (95% CRs). In Mexico, 144,433 and 98,520 individuals are estimated to suffer from NCC-associated epilepsy and NCC-associated severe chronic headaches, respectively. A total of 25,341 (95% CR: 12,569–46,640) DALYs were estimated to be lost due to these clinical manifestations, with 0.25 (95% CR: 0.12–0.46) DALY lost per 1,000 person-years of which 90% was due to NCC-associated epilepsy. This is the first estimate of DALYs associated with NCC in Mexico. However, this value is likely to be underestimated since only the clinical manifestations of epilepsy and severe chronic headaches were included. In addition, due to limited country specific data, some parameters used in the analysis were based on systematic reviews of the literature or primary research from other geographic locations. Even with these limitations, our estimates suggest that healthy years of life are being lost due to NCC in Mexico. Neurocysticercosis (NCC) is a major public health problem caused by the larvae of the parasite Taenia solium. The condition occurs when humans ingest eggs of the pork tapeworm Taenia solium, which then develop into larvae in the central nervous system. The disease is predominantly found and considered important in Latin American, Asian, and African countries and is associated with a large social and economic burden. Very few studies have been conducted to evaluate the burden of NCC and there are no estimates from Mexico. We estimated the disability adjusted life years (DALYs) lost due to NCC in Mexico incorporating morbidity and mortality due to NCC-associated epilepsy, and morbidity due to NCC-associated severe chronic headaches. NCC-associated epilepsy and severe chronic headaches were estimated to cause a loss of approximately 0.25 healthy year of life per 1,000 persons annually in Mexico. This is the first estimate of DALYs associated with NCC in Mexico. However, this value is likely to be underestimated since only the clinical manifestations of epilepsy and severe chronic headaches were included.


  • Quality of Life in Patients with Neurocysticercosis in Mexico

    by Rachana Bhattarai, Christine M. Budke, Hélène Carabin, Jefferson V. Proaño, Jose Flores-Rivera, Teresa Corona, Linda D. Cowan, Renata Ivanek, Karen F. Snowden, Ana Flisser

    The objective of this study was to compare quality of life measures in patients with neurocysticercosis (NCC) to those of a matched control group. The NCC outpatients and their controls were recruited from two neurology referral hospitals in Mexico City, Mexico during 2007–2008. The quality of life of 224 NCC patients was compared with 224 age-sex-hospital-day matched controls using the short form 12 v2 (SF-12 v2) quality of life survey. Medical chart reviews were also conducted for the NCC outpatients to evaluate presenting clinical manifestations. Compared with the controls, NCC patients had a significantly lower score for each of the eight domains of health evaluated and significantly lower Physical and Mental Component Summary scores. Chart reviews indicated that hydrocephalus (48%), severe headaches (47%), and epilepsy (31%) were the most common clinical manifestations in these NCC outpatients.